Next Article in Journal
Ureidopyridazine Derivatives as Acyl-CoA: cholesterol acyltransferase Inhibitors
Previous Article in Journal
Enhanced Role of Grapefruit Juice on the Anti-schistosomal Activity of Artemether on the Liver of Schistosoma haematobium Infected Hamsters
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sci. Pharm.
Volume 76
Issue 2
10.3797/scipharm.0803-21
scipharm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Tirofiban Preserves Endothelial Junctions and Decreases Endothelin-1

by
Jing-Lin ZHAO
,
Yue-Jin YANG
*,
Wei-Dong PEI
,
Yu-Hua SUN
,
Mei ZHAI
,
Ya-Xin LIU
and
Run-Lin GAO
Department of Cardiology, Cardiovascular Institute and Fu-Wai Heart Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2008, 76(2), 171-184; https://doi.org/10.3797/scipharm.0803-21
Submission received: 22 March 2008 / Accepted: 6 May 2008 / Published: 11 May 2008
Versions Notes

Abstract

It has been verified that glycoprotein IIb/IIIa inhibitor tirofiban can attenuate myocardial no-reflow. Myocardial no-reflow has been associated with alterations in endothelial junctions. In addition, ET-1 is an important mechanism for myocardial no-reflow. However, the effect of tirofiban on endothelial junctions and Endothelin-1 (ET-1) is unknown. Methods: Twenty-eight mini-swines were randomized into 3 study groups: 10 in control, 10 given an intravenous infusion of tirofiban and 8 in sham-operated. Acute myocardial infarction and reperfusion model was created with three-hour occlusion of the left anterior descending coronary artery followed by one-hour reperfusion. Results: In control group, plasma ET-1 significantly increased, ET-1 or VE-cadherin level in the reflow and no-reflow myocardium was significantly higher or lower than that in normal myocardium. Compared with the control group, tirofiban significantly decreased plasma ET-1 and myocardial tissue ET-1, maintained VE-cadherin level. Conclusions: Tirofiban is effective in preserving endothelial junction. This beneficial effect of tirofiban could be partly due to its reduction of ET-1.
Keywords: Acute myocardial infarction; Endothelin-1; Reperfusion; Tirofiban; No-reflow Acute myocardial infarction; Endothelin-1; Reperfusion; Tirofiban; No-reflow

Share and Cite

MDPI and ACS Style

ZHAO, J.-L.; YANG, Y.-J.; PEI, W.-D.; SUN, Y.-H.; ZHAI, M.; LIU, Y.-X.; GAO, R.-L. Tirofiban Preserves Endothelial Junctions and Decreases Endothelin-1. Sci. Pharm. 2008, 76, 171-184. https://doi.org/10.3797/scipharm.0803-21

AMA Style

ZHAO J-L, YANG Y-J, PEI W-D, SUN Y-H, ZHAI M, LIU Y-X, GAO R-L. Tirofiban Preserves Endothelial Junctions and Decreases Endothelin-1. Scientia Pharmaceutica. 2008; 76(2):171-184. https://doi.org/10.3797/scipharm.0803-21

Chicago/Turabian Style

ZHAO, Jing-Lin, Yue-Jin YANG, Wei-Dong PEI, Yu-Hua SUN, Mei ZHAI, Ya-Xin LIU, and Run-Lin GAO. 2008. "Tirofiban Preserves Endothelial Junctions and Decreases Endothelin-1" Scientia Pharmaceutica 76, no. 2: 171-184. https://doi.org/10.3797/scipharm.0803-21

APA Style

ZHAO, J. -L., YANG, Y. -J., PEI, W. -D., SUN, Y. -H., ZHAI, M., LIU, Y. -X., & GAO, R. -L. (2008). Tirofiban Preserves Endothelial Junctions and Decreases Endothelin-1. Scientia Pharmaceutica, 76(2), 171-184. https://doi.org/10.3797/scipharm.0803-21

Article Metrics

Back to TopTop